214 related articles for article (PubMed ID: 25473281)
21. Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy.
Xu X; Wu J; Liu Y; Saw PE; Tao W; Yu M; Zope H; Si M; Victorious A; Rasmussen J; Ayyash D; Farokhzad OC; Shi J
ACS Nano; 2017 Mar; 11(3):2618-2627. PubMed ID: 28240870
[TBL] [Abstract][Full Text] [Related]
22. Polydopamine-Based Surface Modification of Novel Nanoparticle-Aptamer Bioconjugates for In Vivo Breast Cancer Targeting and Enhanced Therapeutic Effects.
Tao W; Zeng X; Wu J; Zhu X; Yu X; Zhang X; Zhang J; Liu G; Mei L
Theranostics; 2016; 6(4):470-84. PubMed ID: 26941841
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo evaluation of anti-nucleolin-targeted magnetic PLGA nanoparticles loaded with doxorubicin as a theranostic agent for enhanced targeted cancer imaging and therapy.
Mosafer J; Abnous K; Tafaghodi M; Mokhtarzadeh A; Ramezani M
Eur J Pharm Biopharm; 2017 Apr; 113():60-74. PubMed ID: 28012991
[TBL] [Abstract][Full Text] [Related]
24. Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro.
Yu C; Hu Y; Duan J; Yuan W; Wang C; Xu H; Yang XD
PLoS One; 2011; 6(9):e24077. PubMed ID: 21912664
[TBL] [Abstract][Full Text] [Related]
25. Cell-selective gene silencing in prostate cancer LNCap cells using prostate-specific membrane antigen promoter and enhancer in vitro and in vivo.
Liu R; Sun J; Zhang Z; Xu Y
Cell Biol Int; 2012 Oct; 36(10):863-72. PubMed ID: 22612256
[TBL] [Abstract][Full Text] [Related]
26. Salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers selectively suppress human CD20+ melanoma stem cells.
Zeng YB; Yu ZC; He YN; Zhang T; Du LB; Dong YM; Chen HW; Zhang YY; Wang WQ
Acta Pharmacol Sin; 2018 Feb; 39(2):261-274. PubMed ID: 29388568
[TBL] [Abstract][Full Text] [Related]
27. An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells.
Ara MN; Matsuda T; Hyodo M; Sakurai Y; Hatakeyama H; Ohga N; Hida K; Harashima H
Biomaterials; 2014 Aug; 35(25):7110-20. PubMed ID: 24875764
[TBL] [Abstract][Full Text] [Related]
28. Efficacious delivery of protein drugs to prostate cancer cells by PSMA-targeted pH-responsive chimaeric polymersomes.
Li X; Yang W; Zou Y; Meng F; Deng C; Zhong Z
J Control Release; 2015 Dec; 220(Pt B):704-14. PubMed ID: 26348387
[TBL] [Abstract][Full Text] [Related]
29. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.
Farokhzad OC; Cheng J; Teply BA; Sherifi I; Jon S; Kantoff PW; Richie JP; Langer R
Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6315-20. PubMed ID: 16606824
[TBL] [Abstract][Full Text] [Related]
30. Potential establishment of lung metastatic xenograft model of androgen receptor-positive and androgen-independent prostate cancer (C4-2B).
Yamamichi F; Matsuoka T; Shigemura K; Kawabata M; Shirakawa T; Fujisawa M
Urology; 2012 Oct; 80(4):951.e1-7. PubMed ID: 22920407
[TBL] [Abstract][Full Text] [Related]
31. Study on the cellular internalization mechanisms and
Gu Y; Chen X; Zhang H; Wang H; Chen H; Huang S; Xu Y; Zhang Y; Wu X; Chen J
Drug Deliv; 2020 Dec; 27(1):161-169. PubMed ID: 31913730
[TBL] [Abstract][Full Text] [Related]
32. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers.
Min K; Jo H; Song K; Cho M; Chun YS; Jon S; Kim WJ; Ban C
Biomaterials; 2011 Mar; 32(8):2124-32. PubMed ID: 21147500
[TBL] [Abstract][Full Text] [Related]
33. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles.
Dhar S; Gu FX; Langer R; Farokhzad OC; Lippard SJ
Proc Natl Acad Sci U S A; 2008 Nov; 105(45):17356-61. PubMed ID: 18978032
[TBL] [Abstract][Full Text] [Related]
34. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery.
Cheng J; Teply BA; Sherifi I; Sung J; Luther G; Gu FX; Levy-Nissenbaum E; Radovic-Moreno AF; Langer R; Farokhzad OC
Biomaterials; 2007 Feb; 28(5):869-76. PubMed ID: 17055572
[TBL] [Abstract][Full Text] [Related]
35. Copper sulfide nanoparticle-based localized drug delivery system as an effective cancer synergistic treatment and theranostic platform.
Hou L; Shan X; Hao L; Feng Q; Zhang Z
Acta Biomater; 2017 May; 54():307-320. PubMed ID: 28274767
[TBL] [Abstract][Full Text] [Related]
36. Targeting tumor vasculature with aptamer-functionalized doxorubicin-polylactide nanoconjugates for enhanced cancer therapy.
Tang L; Tong R; Coyle VJ; Yin Q; Pondenis H; Borst LB; Cheng J; Fan TM
ACS Nano; 2015 May; 9(5):5072-81. PubMed ID: 25938427
[TBL] [Abstract][Full Text] [Related]
37. PEG-PLA nanoparticles modified with APTEDB peptide for enhanced anti-angiogenic and anti-glioma therapy.
Gu G; Hu Q; Feng X; Gao X; Menglin J; Kang T; Jiang D; Song Q; Chen H; Chen J
Biomaterials; 2014 Sep; 35(28):8215-26. PubMed ID: 24974009
[TBL] [Abstract][Full Text] [Related]
38. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
39. Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery.
Gu F; Langer R; Farokhzad OC
Methods Mol Biol; 2009; 544():589-98. PubMed ID: 19488725
[TBL] [Abstract][Full Text] [Related]
40. SYL3C aptamer-anchored microemulsion co-loading β-elemene and PTX enhances the treatment of colorectal cancer.
Zhou X; Cao C; Li N; Yuan S
Drug Deliv; 2019 Dec; 26(1):886-897. PubMed ID: 31524012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
